PREVIEW
Since 2000, a new pneumococcal conjugate vaccine has been on the US market, offering immunization against seven serotypes. Its use has the potential to dramatically reduce the incidence of pneumococcal disease and its sequelae in children. Here, the authors review the efficacy, safety, and cost of the new pneumococcal vaccine and offer guidelines on how to incorporate this newer vaccine into today's immunization regimens.